New Study Gives Hope for Less Harmful Breast Cancer Chemo
Researchers recently discovered that lowering the expression of a protein called DSS1, known to be related to the stability of the BRCA2 protein in human cell lines, can improve patients’ responsiveness to chemotherapy, resulting in lower drug doses and fewer adverse effects in patients.
The study’s findings provide vital clues for developing targeted therapy for the lethal condition. Every year, more than 600,000 women worldwide succumb to breast cancer, the most common cancer in women.
BRCA1 and BRCA2 are two genes that influence a person’s risk of developing breast cancer. Typically, these genes’ protein products aid in the repair of DNA damage, lowering the risk of uncontrolled cell growth and tumor development.
Any “mutation” or cellular level anomalies that prevent the BRCA genes from working properly predispose a person to develop breast cancer.
As a result, scientists have been working for decades to understand the role of BRCA genes and the cellular components linked to BRCA1 and BRCA2 proteins in breast cancer growth and develop effective targeted medicines to prevent and treat the illness.
A team of researchers from Japan and the United States has found a protein from the BRCA-associated cellular machinery that plays a crucial role in breast cancer growth.
The researchers first examined a protein complex known as TRanscription–EXport-2 (TREX-2), involved in mRNA transcription and export from the nucleus.
Dr. Kuwahara, the study’s corresponding author, explains that they previously discovered GANP deficiency was linked to breast carcinogenesis. As a result, they wanted to investigate the other TREX-2 complex protein components to see if they had any links to breast cancer.
To put their theories to the test, the researchers carried out several tests that included looking at the expression levels of numerous TREX-2 complex proteins, including DSS1, in breast cancer tissues, as well as cellular level assays.
DSS1 protein expression proved higher in human breast cancer tissues than in normal tissues. In malignant tissues, however, PCID2 protein expression was regular. They also discovered that reduced DSS1 expression is linked to a longer patient survival time.
Interestingly, breast cancer cells with lower DSS1 levels were more sensitive to the anti-cancer medications DXR and PTX, but higher-DSS1-level-breast-cancer cells were resistant to these drugs.
The findings were a watershed moment in the breast-cancer-treatment-research field. These findings give patients with breast cancer hope for a safer age of chemotherapy in the not-too-distant future.
Photo by Thirdman from Pexels